Correlation of PAPP-A values with maternal characteristics, biochemical and ultrasonographic markers of pregrancy

Abstract

Objective: Our aim is to investigate whether there is a correlation of pregnancy-associated plasma protein A (PAPP-A) values with other variables in pregnancy and maternal characteristics. Materials and Methods: We retrospectively analyzed the relation between the pregnancy-associated plasma protein A levels, demographics, biochemical and ultrasonographic markers of the first trimester screening of 11,842 pregnant women seen at a tertiary hospital between November 2002 and November 2008. Results: A significant difference between PAPP-A values of the diabetic and non-diabetic pregnant women were observed (p=0.0005, Mann-Whitney U test). In terms of weight, crown-rump length, BetahCG values, significant differences were observed between low and medium level PAPP-A subgroups and between low and high level PAPP-A subgroups. PAPP-A levels were found to differ significantly between the pregnant women of Caucasian origin and other racial origins. Conclusions: Pregnant women with different ethnic and medical backgrounds have different PAPP-A values and other markers of the aneupleudity screening. To make patient specific risk predictions, understanding these interactions and differences is important. Future studies are needed to understand the pathopyhsiology behind these differences.

Keywords

• Pregnancy-associated plasma protein A (PAPP-A)
• Maternal characteristics
• Aneuploidy screening
• Biochemical markers
• Ultrasonographic markers

References

1. Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancyassociated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab 2002;87:1762-7. doi: 10.1210/ jcem.87.4.8430.
2. Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn 2002;22:778-82. doi: 10.1002/pd.407.
3. Hanita O, Roslina O, Azlin MI. Maternal level of pregnancyassociated plasma protein A as a predictor of pregnancy failure in threatened abortion. Malays J Pathol 2012;34:145-51.
4. Cuckle H, Arbuzova S, Spencer K, et al. Frequency and clinical consequences of extremely high maternal serum PAPP-A levels. Prenat Diagn 2003;23:385-8. doi: 10.1002/pd.600.
5. Westergaard JG, Teisner B, Grudzinskas JG. Serum PAPP-A in normal pregnancy: relationship to fetal and maternal characteristics. Arch Gynecol 1983;233:211-5. doi: 10.1007/ BF02114602.
6. Wright D, Silva M, Papadopoulos S, Wright A, Nicolaides KH. Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015;46:42- 50. doi: 10.1002/uog.14870.
7. Browne JL, Klipstein-Grobusch K, Koster MP, et al. Pregnancy associated plasma protein-a and placental growth factor in a Sub-Saharan African population: A nested cross-sectional study. PLoS ONE 2016;11:e0159592. doi: 10.1371/journal. pone.0159592.
8. Donovan BM, Nidey NL, Jasper EA, et al. First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. PLoS ONE 2018;13: e0201319. doi.org/10.1371/journal.pone.0201319

9. Syngelaki A, Kotecha R, Pastides A, Wright A, Nicolaides KH. First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus. Metabolism 2015;64:1485-9. doi: 10.1016/j.metabol.2015.07.015.
10. DiPrisco B, Kumar A, Kalra B, et al. Placental proteases PAPP-A and PAPP-A2, the binding proteins they cleave (IGFBP-4 and – 5), and IGF-I and IGF-II: Levels in umbilical cord blood and associations with birth weight and length. Metabolism 2019;100:153959. doi: 10.1016/j.metabol.2019.153959.
11. Lovati E, Beneventi F, Simonetta M, et al. Gestational diabetes mellitus: Including serum pregnancy-associated plasma protein-A testing in the clinical management of primiparous women? A case-control study. Diabetes Res Clin Pract 2013;100:340-7. doi: 10.1016/j.diabres.2013.04.002
12. Grewal J, Grantz KL, Zhang C, et al. Cohort profile: NICHD fetal growth studies-singletons and twins. Int J Epidemiol 2018;47:25-25l. doi:10.1093/ije/dyx161
13. Villar J, Papageorghiou AT, Pang R, et al. The likeness of fetal growth and newborn size across non-isolated populations in the INTERGROWTH-21st Project: the Fetal Growth Longitudinal Study and Newborn Cross-Sectional Study. Lancet Diabetes Endocrinol 2014;2:781-92. doi:10.1016/ S2213-8587(14)70121-4
14. Kiserud T, Piaggio G, Carroli G, et al. The World Health Organization Fetal Growth Charts: A Multinational Longitudinal Study of Ultrasound Biometric Measurements and Estimated Fetal Weight [published correction appears in PLoS Med 2017;14 (3):e1002284] [published correction appears in PLoS Med 2017;14 (4):e1002301]. PLoS Med 2017;14(1):e1002220. Published 2017 Jan 24. doi:10.1371/ journal.pmed.1002220
15. Bogin B, Varela-Silva MI. Leg length, body proportion, and health: a review with a note on beauty. Int J Environ Res Public Health 2010;7:1047-75. doi:10.3390/ijerph7031047
16. Clausson B, Lichtenstein P, Cnattingius S. Genetic influence on birthweight and gestational length determined by studies in offspring of twins. BJOG 2000;107:375-81. doi:10.1111/j.1471-0528.2000.tb13234.x.
17. Lunde A, Melve KK, Gjessing HK, Skjaerven R, Irgens LM. Genetic and environmental influences on birth weight, birth length, head circumference, and gestational age by use of population-based parent-offspring data. Am J Epidemiol 2007;165:734-41. doi:10.1093/aje/kwk107
18. Grantz KL, Hediger ML, Liu D, Buck Louis GM. Fetal growth standards: the NICHD fetal growth study approach in context with INTERGROWTH-21st and the World Health Organization Multicentre Growth Reference Study. Am J Obstet Gynecol 2018;218(2S):S641-S655.e28. doi:10.1016/j. ajog.2017.11.593